Welcome to Retinal Associates
Welcome to Retinal Associates, your experts for state-of-the-art retinal care in Springfield, MO. With more than 30 years of experience, Drs. Gary L. Mehlhorn offers a comprehensive approach to the diagnosis and treatment of diseases that affect the retina, macula and vitreous, including:
- Dry macular degeneration
- Wet macular degeneration
- Diabetic retinopathy
- Retinal vein and artery occlusion
Both of our Springfield, MO based retina specialists provide state-of-the-art care to residents of Southwest Missouri and Northwest Arkansas, including treatment with Avastin and Lucentis, as well as the most advanced retinal lasers and eye surgery.
We provide personalized, compassionate care in a comfortable setting and will communicate openly and honestly with you about the treatments we recommend.
Meet our doctor
Read about Dr. Mehlhorn’s education, training and professional accomplishments.
News & Events
The recent fungal meningitis outbreak has been linked to the New England Compounding Pharmacy which sells Avastin. Retinal Associates does not purchase Avastin from this pharmacy, and our pharmacy assures us of their sterility process and accreditations. For more information please follow the link below from the CDC on the current situation:
There have been reports of counterfeited/pirated Avastin using vials with labels (Roche) used in Europe. Reliable vials used in the USA are labeled “Genentech.” We are confident in our supplier who is accredited by the Pharmacy Compounding Accreditation Board. There have been a few reports of increased infection rate post operatively with Avastin injections but we have not experienced any.
New Treatment for Wet Age-related Macular Degeneration
Eylea (aflibercept) was recently released (December ’11) to treat wet macular degeneration. Six and a half years ago Lucentis, the first FDA approved treatment for AMD was released. Shortly afterwards Avastin became increasingly used as a less expensive alternative off-label drug. Last March an independent study verified that Avastin and Lucentis were equally effective in maintaining vision when used on a monthly basis.
Eylea has been shown to be as effective when given every two months. This may mean less frequent injections in the future. All these medications block the growth of abnormal leaking vessels that cause wet macular degeneration.
Eylea is almost as costly as Lucentis at $1850 a dose while Avastin costs approximately $50. Medicare and most insurance carriers approve all these regimens for wet AMD.